New cancer drug shows promise in early trial
NCT ID NCT02952248
First seen Jan 31, 2026 · Last updated Jun 23, 2026 · Updated 21 times
Summary
This early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs that the drug might shrink tumours.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, H2X 0A9, Canada
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Greenville Health System
Greenville, South Carolina, 29605, United States
-
Ingalls Memorial Hospital
Harvey, Illinois, 60426, United States
-
Juravinski Cancer Centre - Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
The Christie Hospital
Manchester, M20 4BX, United Kingdom
-
The Ottawa Hospital
Ottawa, Ontario, K1H 8L6, Canada
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 754091 (ezabenlimab), an immunotherapy drug
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumours that have not responded to other therapies.
What could go wrong
This is an early Phase I trial focused on safety and dosing, not on proving effectiveness. The drug may not shrink tumours or could cause significant side effects. Results may not apply to all cancer types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.